Pichaya Tantiyavarong

Dr. Pichaya Tantiyavarong


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
PTPichaya Tantiyavarong
Pichaya Tantiyavarong
OTOpas Traitanon
Opas Traitanon
PCPiyatida Chuengsaman
Piyatida Chuengsaman
JPJayanton Patumanond
Jayanton Patumanond
ATAdis Tasanarong
Adis Tasanarong
Background. Patients with peritoneal dialysis-related peritonitis usually have different responses to initial antibiotic treatment. This study aimed to explore the patterns of response by using the changes of dialysate white blood cell count on the first five days of the initial antibiotic treatment.Materials and Methods. A retrospective cohort study was conducted. All peritoneal dialysis-related peritonitis episodes from January 2014 to December 2015 were reviewed. We categorized the patterns of antibiotic response into 3 groups: early response, delayed response, and failure group. The changes of dialysate white blood cell count for each pattern were determined by multilevel regression analysis.Results. There were 644 episodes in 455 patients: 378 (58.7%) of early response, 122 (18.9%) of delayed response, and 144 (22.3%) of failure episodes. The patterns of early, delayed, and failure groups were represented by the average rate reduction per day of dialysate WBC of 68.4%, 34.0%, and 14.2%, respectively (pvalue < 0.001 for all comparisons).Conclusion. Three patterns, which were categorized by types of responses, have variable rates of WBC declining. Clinicians should focus on the delayed response and failure patterns in order to make a decision whether to continue medical therapies or to aggressively remove the peritoneal catheter.

24 May 2023 in Frontiers in Pediatrics
Verified
Journal Article
Open access
TLTananya Lokanuwatsatien
Tananya Lokanuwatsatien
ASAraya Satdhabudha
Araya Satdhabudha
ATAuchara Tangsathapornpong
Auchara Tangsathapornpong
PBPornumpa Bunjoungmanee
Pornumpa Bunjoungmanee
PSPhakatip Sinlapamongkolkul
Phakatip Sinlapamongkolkul
PTPichaya Tantiyavarong
Pichaya Tantiyavarong
Introduction: The number of pediatric COVID-19 infections is increasing; however, the data on long COVID conditions in children is still limited. Our study aimed to find the prevalence of long COVID in children during the Delta and Omicron waves, as well as associated factors.Methods: A single-center prospective cohort study was conducted. We included 802 RT-PCR-confirmed COVID-19 pediatric patients in the Delta and Omicron periods. Long COVID was defined as having symptoms for ≥3 months after infection. Parents and/or patients were interviewed by phone. Multivariable logistic regression was performed to find associated factors with long COVID.Results: The overall prevalence of long COVID was 30.2%. The Delta period had more prevalence than the Omicron (36.3% vs. 23.9%). Common symptoms for patients 0–3 years’ old were loss of appetite, rhinorrhea, and nasal congestion. Conversely, patients 3–18 years’ old had hair loss, dyspnea on exertion, rhinorrhea, and nasal congestion. However, there was no significant negative impact on daily life. Most symptoms improved after a 6-month follow-up. Factors associated with long COVID-19 conditions were infection during the Omicron period (adjusted OR: 0.54; 95% CI: 0.39–0.74, P < 0.001), fever (adjusted OR: 1.49, 95% CI: 1.01–2.20, P = 0.04) and rhinorrhea (adjusted OR: 1.47, 95% CI: 1.06–2.02, P = 0.02).Conclusion: Infection during the Omicron wave has a lower prevalence of long COVID. The prognosis is often favorable, and most symptoms gradually become less. However, pediatricians may schedule appointments to surveil long COVID in children with fever or rhinorrhea as an initial symptom.

23 January 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SASuthiya Anumas
Suthiya Anumas
ACAphichat Chatkrailert
Aphichat Chatkrailert
PTPichaya Tantiyavarong
Pichaya Tantiyavarong
In patients on chronic hemodialysis, there is no standard protocol for maintenance iron supplementation. This study aimed to compare two fixed-dose intravenous (IV) iron protocols to reduce erythropoiesis-stimulating agents (ESA). We conducted a double-blinded, randomized controlled study on hemodialysis patients having ferritin levels between 200 and 700 ng/dl and transferrin saturation values between 20 and 40%. Patients were assigned to receive either 100 or 200 mg of IV iron each month. ESA was adjusted every month to keep Hb between 10 and 12 g/dl. ESA dose at 12 months was the primary outcome. The secondary outcomes were all-cause mortality, cardiovascular events, absolute iron deficiency anemia (IDA), blood transfusion, adverse events, and iron withholding rate. Of the 79 eligible patients, 40 received 100 mg of IV iron, while 39 received 200 mg. At month 12, the mean monthly ESA dose in the 100-mg IV iron group was 35,706 ± 21,637 IU, compared to 26,382 ± 14,983 IU in the 200-mg group (P = 0.03). IDA was found in twelve patients (30%) in the 100-mg group and four patients (10.5%) in the 200-mg group (P = 0.05). In each group, three patients died (P = 0.9). Hospitalization, venous access thrombosis, and infection rates were similar in both groups. The withholding rate of IV iron was higher in 200-mg group (25% vs. 64.1%), but the protocol compliance was found more in 100-mg group (50% vs. 28.2%) (P = 0.001). In conclusion, monthly 200-mg IV iron infusions significantly reduce ESA doses but have a higher withholding rate. (Funded by the Kidney Foundation of Thailand and the Research Group in Nephrology and Renal Replacement Therapy from the Faculty of Medicine, Thammasat University).Thai Clinical Trials Registry number, TCTR20190707001.

1 July 2019 in Clinical Kidney Journal
Verified
Journal Article
Open access
PTPichaya Tantiyavarong
Pichaya Tantiyavarong
AKAnneke Kramer
Anneke Kramer
JHJames G Heaf
James G Heaf
PFPatrik Finne
Patrik Finne
AÅAnders Åsberg
Anders Åsberg
MNMarlies Noordzij
Marlies Noordzij
Background: Kidney transplantation should improve abnormalities that are common during dialysis treatment, like anaemia and mineral and bone disorder. However, its impact is incompletely understood. We therefore aimed to assess changes in clinical indicators after the transition from chronic dialysis to kidney transplantation.Methods: We used European Renal Association–European Dialysis and Transplant Association Registry data and included adult dialysis patients for whom data on clinical indicators before and after transplantation (2005–15) were available. Linear mixed models were used to quantify the effect of transplantation and of time after transplantation for each indicator.Results: In total, 16 312 patients were included. The mean age at transplantation was 50.1 (standard deviation 14.2) years, 62.9% were male and 70.2% were on haemodialysis before transplantation. Total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglycerides increased right after transplantation but decreased thereafter. All other indicators normalized or approached the target range soon after transplantation and these improvements were sustained for the first 4 years of follow-up. In patients with higher estimated glomerular filtration rate (eGFR) levels (30–60 and >60 mL/min/1.73 m2), the improvement of haemoglobin, ferritin, ionized calcium, phosphate, parathyroid hormone, HDL cholesterol, triglycerides, albumin and C-reactive protein levels was more pronounced than in patients with a lower eGFR (<30 mL/min/1.73 m2).Conclusions: Except for total cholesterol, LDL cholesterol and triglycerides, all clinical indicators improved after transplantation. These improvements were related to eGFR. Nevertheless, values remained out of range in a considerable proportion of patients and anaemia and hyperparathyroidism were still common problems. Further research is needed to understand the complex relationship between eGFR and the different clinical indicators.

1 March 2023 in JCO Global Oncology
Verified
Journal Article
Open access
WTWalaipan Tantiyavarong
Walaipan Tantiyavarong
PSPrakongboon Sungkasubun
Prakongboon Sungkasubun
WCWorawit Chaiwiriyawong
Worawit Chaiwiriyawong
ASArchara Supavavej
Archara Supavavej
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
CSChayanee Samdaengpan
Chayanee Samdaengpan
PURPOSE: The COVID-19 pandemic has affected public health worldwide. The efficacy and safety of COVID-19 vaccines have been evaluated in the general population; however, data on patients with malignancies are limited. METHODS: This prospective longitudinal observational cohort study was conducted between June and July 2021. Enrolled adult patients with cancer were divided into chemotherapy and nonchemotherapy groups. All participants were immunized with two doses of the ChAdOx1 nCoV-19 or CoronaVac COVID-19 vaccines. The primary outcome was a comparison of the immunogenicity (as assessed by spike protein [anti-S] immunoglobulin G [IgG] antibody titers) of two doses of COVID-19 vaccine in the chemotherapy and nonchemotherapy groups. The secondary outcomes included the anti-S IgG seroconversion rate and vaccine safety in both groups. RESULTS: Among the 173 enrolled patients with solid cancer, after COVID-19 vaccination, the chemotherapy group had a significantly lower median anti-S IgG titer than the nonchemotherapy group (26 v 237 U/mL, P < .001). A statistically significant difference in anti-S IgG titer was found between groups vaccinated with CoronaVac (7 v 90 U/mL, P < .001), but no difference was found in those vaccinated with ChAdOx1 nCoV-19 (818 v 1061 U/mL, P = .075). The anti-S IgG seroconversion rate was significantly lower in the chemotherapy group than that in the nonchemotherapy group (78.9% v 96.5%, P = .001). No new or serious vaccine-related adverse events were reported. CONCLUSION: Patients with solid cancer receiving a COVID-19 vaccine while undergoing chemotherapy had lower immunogenicity responses to vaccination than those who were vaccinated while undergoing nonchemotherapy treatment. No statistically significant difference was observed in the COVID-19 vaccine safety profiles between groups.

19 March 2025 in Kidney360
Verified
Journal Article
Open access
PAPeemai Amornkanjanawat
Peemai Amornkanjanawat
SKStephen Kerr
Stephen Kerr
TWThunyatorn Wuttiputhanun
Thunyatorn Wuttiputhanun
NTNatavudh Townamchai
Natavudh Townamchai
ALAsada Leelahavanichkul
Asada Leelahavanichkul
SUSuwasin Udomkarnjananun
Suwasin Udomkarnjananun
Key Points: Kidney allograft rejection is an independent risk factor for post-transplant cardiovascular events (CVEs), regardless of kidney allograft function. Time-updated post-transplant variables were more associated with post-kidney transplantation CVEs than using the pretransplant variables only. Proper screening protocol for high-risk recipients may be necessary to reduce the incidence of post-kidney transplantation CVEs. Background: Cardiovascular death is the leading cause of mortality in kidney transplant recipients (KTRs). Although risk factors for post-transplant cardiovascular events (CVEs) have been established, previous studies primarily focused on factors at the time of transplantation without integrating post-transplant factors into the analyses. In addition, most studies were conducted in a mixed population of cyclosporine A and tacrolimus-based immunosuppression, which have different metabolic effects. This study aims to evaluate factors for post-transplant CVEs, including both pretransplant and post-transplant variables, specifically in a population of KTRs receiving tacrolimus-based immunosuppression. Methods: Competing risk regression was performed modeling participant demographics, transplant characteristics, and post-transplant time-updated variables. The primary outcome was the composite of post-transplant CVEs, which included myocardial infarction, heart failure, ischemic stroke, peripheral arterial disease, and cardiovascular death. Results: The incidence of post-transplant CVEs was 15.88 per 1000 patient-years among 553 KTRs included in the study. Key factors significantly associated with post-transplant CVEs included recipient age, diabetes mellitus status, post-transplant hemoglobin A1c, 24-hour urine creatinine clearance, post-transplant serum calcium, and rejection. KTRs with a history of T-cell–mediated rejection or antibody-mediated rejection were at a three-fold (95% confidence interval, 1.22 to 7.37; P value 0.016) and 3.38-fold (95% confidence interval, 1.13 to 10.09; P value 0.029) higher risk for post-transplant CVEs, respectively. Compared with models using pretransplant factors alone, models that included both pretransplant and post-transplant variables demonstrated significantly higher prediction performance. Conclusions: Allograft rejections significantly increased the risk of post-transplant CVEs. Surveillance protocols for post-transplant CVEs should include KTRs with a history of allograft rejection, in addition to the traditional high-risk groups.